German pharmaceutical “CureVac” guarantees global access to potential COVID-19 vaccine, following high bids from the United States to secure exclusive rights
US President Donald Trump offered a large amount of money to the German biopharmaceutical company CureVac to secure the lab’s work on a COVID-19 vaccine exclusively for the US. The German government, in turn, made financial offers to keep CureVac in Germany. On March 15, 2020, CureVac’s biggest investor, Dietmar Hopp, stated that there will be no exclusive contract with the US: "We want to develop a vaccine for the whole world and not individual countries."
CureVac is is likely to enter the test phase for its COVID-19 vaccine in June or July 2020.